Pharma Focus Asia

Samsung Biologics Invests US $1.46 billion (KRW 1.9 trillion) for the Construction of Fifth New Plant

Samsung Biologics plans for the contruction of fifth new plant. The new site will be located at Songdo, South Korea.

The new facility is the second Bio campus covering an area of 96,000m2 and holding a capacity of 180,000 litres.

The plant is expected to further maximise its operational efficiency, allowing to leverage existing talent, knowledge and technology gained through the plant's 1 to experience, while implementing advanced digitisation and sustainability capabilities.

This new facility will help customers with even greater innovation and services that will increase speed to the current market and flexibility.

The current Plants 1, 2, and 3 are under near-full utilisation and Plant 4 started partial operations in October last year, and is expected to be fully operational by the middle of the year.

The contruction of the new facility begins in first half of 2023 and expected to be start its operations in 2025.


NameSamsung Biologics
TypeNew Construction
Budget$1.46 billion (KRW 1.9 trillion)
Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Adopting the Power of AI to Drug Development ProjectsROUQETTE - Pharma Virtual LabDUPHAT 2024Thermo Fisher Scientific - Rapid Mycoplasma TestingAsia Healthcare Week 20247th Annual Pharma Project & Portfolio Management 2024CHEMICAL INDONESIA 2024INALAB 2024The Drug Safety Symposium 2024Medlab Middle East 2024ISPE Singapore Affiliate Conference & Exhibition 2024